Showing 15 posts of 52 posts found.


Janssen’s party drug-based nasal spray becomes first new FDA-approved depression treatment in 30 years

March 6, 2019
Research and Development, Sales and Marketing Janssen, Spravato, depression, esketamine, pharma

The field of depression therapy has seen its biggest leap forward in over three decades, the FDA approval of Janssen’s …

Researchers activate gene to reverse depression in mice

February 18, 2019
Sales and Marketing SIRT1, depression, genetics, mental health

Scientists at the Medical College of Georgia at Augusta University were able to directly activate a gene associated with depression …


Janssen’s esketamine drug recommended by FDA panel for depression

February 13, 2019
Research and Development, Sales and Marketing FDA, Janssen, Spravato, depression, esketamine, major depressive disorder, pharma

In a rare and welcomed development in the treatment of major depressive disorder (MDD), Janssen has announced that its esketamine …


Psychedelic therapy: A new approach to mental health

December 10, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing LSD, MDMA, controlled substances, depression, mental health, pharma, psychotherapy

In November 2018, a Phase 2 clinical trial found that 76% of patients who underwent MDMA-assisted psychotherapy no longer had …


GSK’s anti-seizure drug shows promise in early depression study

November 2, 2018
Medical Communications, Research and Development GSK, GlaxoSmithKline, Potiga, depression, pharma

Researchers have found that GlaxoSmithKline’s ezogabine (Potiga), approved by the FDA in 2011 as an anti-seizure therapy, could have applications …


Committee advises against FDA approval of Alkermes’ novel depression drug

November 2, 2018
Medical Communications, Sales and Marketing Alkermes, FDA, depression, pharma

Alkermes has been knocked back with the disappointing, though not entirely unexpected, news that the FDA-appointed Psychopharmacologic Drugs Advisory Committee …


Ketamine’s antidepressant effects may be linked to brain’s opioid system

September 6, 2018
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Ketamine, antidepressant, depression, mental health, opioid

Ketamine’s antidepressant effect works through the activation of the brains opioid receptors, a new study published in The American Journal …


Nerve stimulation treatments improve quality of life in depressed people, study shows

August 23, 2018
Research and Development VNS, depression, neuroscience, psychiatry, quality of life, vagus nerve stimulators

Nerve stimulation treatments can significantly improve depressed people’s quality of life, even in cases in which an individual continues to …


J&J’s ketamine-based antidepressant showed mixed success at Phase 3

May 8, 2018
Manufacturing and Production, Research and Development, Sales and Marketing J&J, JJ, Johnson & Johnson, Ketamine, antidepressant, depression, esketamine, pharma

Johnson & Johnson has revealed new data on its new depression drug esketamine, its chemically ‘left-handed’ version of the controlled …


Alkermes sent reeling as FDA refuses review of depression treatment

April 3, 2018
Manufacturing and Production, Research and Development, Sales and Marketing Alkermes, FDA, depression, major depressive disorder, pharma

Alkermes shares were knocked down to their lowest level since October 2016 after it was revealed that the FDA had …


NICE recommends for online and mobile depression programme for trial on NHS

January 24, 2018
Research and Development Deprexis, NHS, NICE, app, depression, pharma

NICE has said that a new online and mobile app should be trialled on the NHS in the treatment of …

J&J’s predicted blockbuster depression posts P2 data

January 3, 2018
Research and Development Johnson & Johnson, biotech, depression, drugs, pharma, pharmaceutical

Johnson & Johnson has revealed Phase 2 data for its treatment for depression, esketamine, and the results are positive. The …


NHS talking therapies for mental health hit a high with 1.4 million referrals

December 5, 2017
Manufacturing and Production, Medical Communications NHS, anxiety, depression, mental illness, pharma

New data has revealed that the number of UK patients seeking talking therapies on the NHS is on the rise, …


First large-scale study gives hope for ketamine as a depression therapy

May 3, 2017
Research and Development Ketamine, depression, mental health

While the development of truly innovative mental health therapies has ground to a halt somewhat, scientific research in the field …

Latest content